Association of T174M polymorphism of angiotensinogen gene with essential hypertension: a meta-analysis

Abstract

The association between T174M polymorphism of angiotensinogen gene and essential hypertension risk remains controversial. We herein performed a meta-analysis to achieve a reliable estimation of their relationship. All the studies published up to May 2013 on the association between T174M polymorphism and essential hypertension risk were identified by searching the electronic repositories PubMed, MEDLINE and EMBASE, Springer, Elsevier Science Direct, Cochrane Library and Google Scholar. Data were extracted and pooled odds ratios (ORs) with 95% confidence intervals (95% CIs) were calculated. Ultimately, nine eligible studies, including 2188 essential hypertension cases and 2459 controls, were enrolled in this meta-analysis. No significant associations were found under the overall ORs for M-allele comparison (M vs. T, pooled OR 0.92, 95% CI 0.62–1.37), MM vs. TT (pooled OR 0.86, 95% CI 0.29–2.51), TM vs. TT n (pooled OR 0.91, 95% CI 0.63–1.32), recessive model (MM vs. TT+TM, pooled OR 0.89, 95% CI 0.35–2.30), dominant model (MM+TM vs. TT, pooled OR 0.91, 95% CI 0.60–1.38) between T174M polymorphism and risk for essential hypertension. This meta-analysis suggested that the T174M polymorphism of the angiotensinogen gene might not be associated with the susceptibility of essential hypertension in Asian or European populations.

Risk given byAGTpolymorphisms in inducing susceptibility to essential hypertension among isolated populations from a remote region of China: A case-control study among the isolated populations

“…68,72 Besides, other research, among the rural Chinese, 84 Americans in Ontario OjiCree, 116 Canadian Caucasians, 117 and Europeans, 118 showed the associations between the T174M polymorphism and glomerular filtration rate, the risk of metabolic syndrome, heart failure, and myocardial infarction, respectively. In contrast, other studies, among the populations of northern Chinese Han individuals, 64,85 Asians, 39 Europeans, 39 African Americans, 33 and European Americans, 33 have indicated the absence of association of T174M with EH. In addition, other studies, among the Mexicans, 26 black and white participants, 119 Americans in the Delaware Valley Region, 106 Americans, 120 Caucasians, 121 Chinese Han, 122 and Taiwanese, 89 showed no association between this polymorphism and the risk of the non-familial atrial fibrillation, lower extremity arterial disease, decline in renal function post-transplantation, preeclampsia, pseudoxanthoma elasticum, coronary artery disease, and chronic kidney disease in this mutation, respectively.…”

Association of A-20C polymorphism in the angiotensinogen gene with essential hypertension: a meta-analysis

“…AGT is the major effector molecule of the RAS (Gu et al, 2011). Previous research has focused mainly on the M235T and T174M polymorphisms in the AGT gene (Mondry et al, 2005;Liao et al, 2014). Since M235T and T174M are located far from the rennin cleavage site, these 2 polymorphisms in the AGT gene do not fully explain the molecular mechanisms responsible for increased plasma AGT levels (Li et al, 2013).…”

“…The AGT gene is located at lq42-43, and consists of five exons (Benigni et al, 2010). Previous meta-analyses have indicated an association between the M235T and T174M polymorphism in the AGT gene and an increased risk of hypertension (Mondry et al, 2005;Liao et al, 2014). However, the pathogenesis of the RAS gene in the involvement of hypertension could not be fully explained by these polymorphisms.…”

Polymorphism of ACE, AGT, AGTR1 genes as genetic predictors of hypertension

“…Учитывая то, что генетическая информация человека в значительной степени стабильна с рождения, она может выступать как ранний предиктор риска развития гипертонии. Идентификация полиморфных вариантов генов, ассоциированных с высоким риском ее развития, может быть одним из перспективных направлений ранней диагностики и профилактики данного заболевания, кроме того, наличие данной информации позволит уточнить прогноз лиц, уже страдающих данным заболеванием, а также персонифицировать подход к лечению пациента [1,3,[7][8][9][10]. Подобный персонифицированный подход к лечению, основанный на полученной исследователями информации о различных эффектах лекарственных препаратов, в зависимости от генома конкретного индивидуума, является важнейшей задачей фармакогеномики.…”